We are live on ! Find out more
Barclays

Barclays Portfolio holdings

AUM $416B
1-Year Est. Return 33.63%
 

Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.

This Fund
S&P 500
This Quarter Est. Return
+11.71%
1 Year Est. Return
+33.63%
3 Year Est. Return
+104.86%
5 Year Est. Return
+133.18%
10 Year Est. Return
+529.74%
AUM
$461B
AUM Growth
+$24.9B
Cap. Flow
-$12.1B
Cap. Flow %
-2.62%
Top 10 Hldgs %
40.03%
Holding
5,800
New
615
Increased
1,596
Reduced
2,751
Closed
340

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$2.34B
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$1.65B
3
TSLA icon
Tesla
TSLA
+$1.45B
4
QQQ icon
Invesco QQQ Trust
QQQ
+$1.01B
5
AAPL icon
Apple
AAPL
+$833M

Sector Composition

Rank Sector Weight
1 Technology 20.48%
2 Financials 7.27%
3 Consumer Discretionary 6.82%
4 Communication Services 5.06%
5 Healthcare 4.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AYTU icon
5301
AYTU BioPharma
AYTU
$22.3M
$2 ﹤0.01%
1
BAER icon
5302
Bridger Aerospace
BAER
$109M
$2 ﹤0.01%
1
CRIS icon
5303
Curis
CRIS
$9.71M
0
DTI icon
5304
Drilling Tools International
DTI
$80.5M
$2 ﹤0.01%
1
-1,585
-100% -$3.49K
INO icon
5305
Inovio Pharmaceuticals
INO
$85.6M
$2 ﹤0.01%
1
-81
-99% -$155
JSPR icon
5306
Jasper Therapeutics
JSPR
$20M
$2 ﹤0.01%
1
LCTX icon
5307
Lineage Cell Therapeutics
LCTX
$264M
$2 ﹤0.01%
1
-26,438
-100% -$31.3K
NERV icon
5308
Minerva Neurosciences
NERV
$191M
$2 ﹤0.01%
+1
New +$2
OBIO icon
5309
Orchestra BioMed
OBIO
$228M
$2 ﹤0.01%
1
-873
-100% -$2.41K
PROK icon
5310
ProKidney
PROK
$316M
$2 ﹤0.01%
1
PRPL icon
5311
Purple Innovation
PRPL
$34.5M
0
QRHC icon
5312
Quest Resource Holding
QRHC
$27.6M
$2 ﹤0.01%
1
-1,402
-100% -$2.6K
RDZN icon
5313
Roadzen
RDZN
$98.1M
$2 ﹤0.01%
2
SES icon
5314
SES AI
SES
$187M
$2 ﹤0.01%
1
SWVLW icon
5315
Swvl Holdings Corp Warrant
SWVLW
$143K
$2 ﹤0.01%
238
SYBX
5316
DELISTED
Synlogic
SYBX
$2 ﹤0.01%
+1
New +$1
TNYA icon
5317
Tenaya Therapeutics
TNYA
$160M
$2 ﹤0.01%
1
-9,536
-100% -$9.61K
BOLD
5318
Boundless Bio
BOLD
$55.7M
$2 ﹤0.01%
2
DLPN icon
5319
Dolphin Entertainment
DLPN
$13.4M
$1 ﹤0.01%
+1
New +$1
KNDI
5320
Kandi Technologies Group
KNDI
$66.5M
$1 ﹤0.01%
1
ORGN
5321
DELISTED
Origin Materials
ORGN
0
OTLK icon
5322
Outlook Therapeutics
OTLK
$187M
$1 ﹤0.01%
1
-100
-99% -$173
PSTV icon
5323
Plus Therapeutics
PSTV
$25M
-4
Closed -$49
SGMO
5324
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1 ﹤0.01%
1
WKHS icon
5325
Workhorse Group
WKHS
$33.4M
0

Similar funds

Barclays's Q3 2025 Portfolio in Review

As of Q3 2025, Barclays held 5,800 positions worth $461B, up 5.7% from $436B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Barclays's Q3 2025 filing shows 615 new, 1,596 increased, 2,751 reduced and 340 closed positions. Its largest new stake was Paramount Skydance Corp: 13,646,704 shares worth $258M. The largest sale was NVIDIA, an estimated $2.34B.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Barclays's largest Q3 2025 buy was Paramount Skydance Corp: 13,646,704 shares worth $258M.
  • Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2025, an estimated $712M increase.
  • Barclays's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $2.34B.
  • Barclays fully exited Blueprint Medicines in Q3 2025, selling an estimated $200M.
  • Barclays's ten largest holdings make up 40% of its $461B portfolio in Q3 2025.
  • Barclays opened 615 new positions and closed 340 in Q3 2025.
  • Barclays's portfolio value rose 5.7% quarter-over-quarter to $461B.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.